or Try an Advanced Search...

    Treatment Of Cancer Stocks List

    Symbol Grade Name % Change
    ALPN A Alpine Immune Sciences, Inc. 0.19
    CATX A Perspective Therapeutics, Inc. 2.04
    MACK A Merrimack Pharmaceuticals, Inc. 0.27
    STTK A Shattuck Labs, Inc. -5.43
    EXEL A Exelixis, Inc. 0.13
    GTHX A G1 Therapeutics, Inc. -1.44
    RNA A Avidity Biosciences, Inc. -1.35
    CNTX A Context Therapeutics Inc. -6.38
    NRIX B Nurix Therapeutics, Inc. -5.89
    LIXT B Lixte Biotechnology Holdings, Inc. 3.40
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Scientific & Technical Instruments Shell Companies
    Related Stock Lists: Cancer Biotechnology Biopharmaceutical Breast Cancer Life Sciences Medicine Clinical Development Clinical Medicine Disease Her2 Her2/Neu Lymphoma Protein Kinase Inhibitor Small Molecule Therapies Treatment Of Breast Cancer Tyrosine Kinase Advanced Solid Tumors Antibodies Antiestrogens Antineoplastic Drugs

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Cancer stocks.

    Symbol Grade Name Weight
    MOON F Direxion Moonshot Innovators ETF 6.97
    PTH D Invesco DWA Healthcare Momentum ETF 6.61
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 6.6
    IDNA D iShares Genomics Immunology and Healthcare ETF 4.72
    SBIO D ALPS Medical Breakthroughs ETF 4.12
    View all Treatment Of Cancer ETFs...
    Compare ETFs
    Compare BBC to IDNA Compare MOON to IDNA Compare MOON to SBIO

        Treatment Of Cancer Stocks Recent News

        Date Stock Title
        Apr 19 GTHX G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit
        Apr 18 RNA To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
        Apr 18 STTK Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),
        Apr 18 ALPN Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
        Apr 17 EXEL Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth
        Apr 17 GTHX G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
        Apr 16 NRIX Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
        Apr 16 EXEL Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
        Apr 15 ALPN Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
        Apr 15 NRIX Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
        Apr 15 NRIX Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
        Apr 13 ALPN Could This Stock Be the Next Biotech Buyout?
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Scientific & Technical Instruments Shell Companies
        Related Stock Lists: Cancer Biotechnology Biopharmaceutical Breast Cancer Life Sciences Medicine Clinical Development Clinical Medicine Disease Her2 Her2/Neu Lymphoma Protein Kinase Inhibitor Small Molecule Therapies Treatment Of Breast Cancer Tyrosine Kinase Advanced Solid Tumors Antibodies Antiestrogens Antineoplastic Drugs
        Treatment Of Cancer

        Treatment of cancer depends on the type and stage of the cancer, as well as the patient's overall health and preferences. Treatment options may include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and/or hormone therapy. In some cases, a combination of treatments may be used.

        Browse All Tags